These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36275037)

  • 21. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis.
    Gulati K; Edwards H; Prendecki M; Cairns TD; Condon M; Galliford J; Griffith M; Levy JB; Tam FWK; Tanna A; Pusey CD; McAdoo SP
    Kidney Int; 2021 Dec; 100(6):1316-1324. PubMed ID: 34560140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
    Hansrivijit P; Cheungpasitporn W; Thongprayoon C; Ghahramani N
    BMC Nephrol; 2020 Apr; 21(1):134. PubMed ID: 32293308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
    Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
    Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?
    Del Vecchio L; Allinovi M; Rocco P; Brando B
    J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
    Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
    J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nephrotic syndrome and rituximab: facts and perspectives.
    Haffner D; Fischer DC
    Pediatr Nephrol; 2009 Aug; 24(8):1433-8. PubMed ID: 19495800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Journal Club Review of "Avacopan for the Treatment of ANCA-Associated Vasculitis".
    Soulsby WD
    ACR Open Rheumatol; 2022 Jul; 4(7):558-561. PubMed ID: 35167187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [An innovative approach to the treatment of immune-mediated glomerular diseases].
    Roccatello D
    G Ital Nefrol; 2013; 30(1):. PubMed ID: 23832439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
    Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Membranous Nephropathy: It Is Time to Go Back to the Future.
    Sabiu G; Podestà MA
    Nephron; 2021; 145(6):721-727. PubMed ID: 34225270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B cell depletion: rituximab in glomerular disease and transplantation.
    Marinaki S; Skalioti C; Boletis JN
    Nephron Extra; 2013 Jan; 3(1):125-30. PubMed ID: 24550930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis.
    Bose B; Chung EYM; Hong R; Strippoli GFM; Johnson DW; Yang WL; Badve SV; Palmer SC
    J Nephrol; 2022 May; 35(4):1159-1170. PubMed ID: 35199314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction treatment of ANCA-associated vasculitis with a single dose of rituximab.
    Turner-Stokes T; Sandhu E; Pepper RJ; Stolagiewicz NE; Ashley C; Dinneen D; Howie AJ; Salama AD; Burns A; Little MA
    Rheumatology (Oxford); 2014 Aug; 53(8):1395-403. PubMed ID: 24609057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interstitial nephritis without glomerulonephritis in ANCA-associated vasculitis: a case series and literature review.
    He X; Wen Y; Hu R; Wu H; Ye W; Yue C; Qin Y; Xia P; Chen L
    Clin Rheumatol; 2022 Nov; 41(11):3551-3563. PubMed ID: 35759125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report.
    Harris C; Marin J; Beaulieu MC
    BMC Nephrol; 2018 Jun; 19(1):152. PubMed ID: 29954345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab.
    Yoshida S; Hanai S; Nakagomi D; Kobayashi K; Takahashi K; Furuya F
    Intern Med; 2021 Jan; 60(1):145-150. PubMed ID: 32830174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Thietart S; Karras A; Augusto JF; Philipponnet C; Carron PL; Delbrel X; Mesbah R; Blaison G; Duffau P; El Karoui K; Smets P; London J; Mouthon L; Guillevin L; Terrier B; Puéchal X;
    JAMA Netw Open; 2022 Jul; 5(7):e2220925. PubMed ID: 35802372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [KDIGO 2021 guideline glomerulonephritis - focus on ANCA-associated vasculitides and anti-glomerular basement membrane glomerulonephritis].
    de Groot K; Haubitz M; Rupprecht HD; Schönermarck U
    Dtsch Med Wochenschr; 2021 Nov; 146(23):1552-1558. PubMed ID: 34826843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Rovin BH; Caster DJ; Cattran DC; Gibson KL; Hogan JJ; Moeller MJ; Roccatello D; Cheung M; Wheeler DC; Winkelmayer WC; Floege J;
    Kidney Int; 2019 Feb; 95(2):281-295. PubMed ID: 30665569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.